New drug cocktail aims to shrink inoperable lung tumors enough for surgery
NCT ID NCT06706219
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, in 50 people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if the treatment can shrink tumors enough to allow surgery, and to measure how long the cancer stays under control. Participants will receive the drugs intravenously, and researchers will track side effects and survival rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Provincal Tumor Hospital
Changsha, Hunan, 410013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to keep lung cancer at bay
- Step counts may predict trouble during lung cancer therapy
- New pill targets Hard-to-Treat lung cancer in patients who Can't have standard therapy
- New combo therapy aims to stop lung cancer from returning
- Blood test guides new attack on lung cancer return
- Real-World study tracks immune response in lung cancer patients after standard treatment